Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)

    Stratifies patients with chronic lymphocytic leukemia into four risk categories.
    Favorite
    When to Use
    Pearls/Pitfalls
    Why Use

    Patients with new diagnosis of chronic lymphocytic leukemia (CLL), to estimate prognosis and time to first treatment.

    • Developed using patient data from before use of targeted agents such as ibrutinib and venetoclax, which are known to have greater efficacy in patients with TP53 alterations.
    • While treatment type was not an independent factor in the CLL-IPI, TP53 status was, and thus the use of novel agents may have an effect not currently measured in the CLL-IPI.

    Many patients with CLL will have an indolent course and not require treatment for many years, while others will have a shorter time to first treatment. The CLL-IPI combines clinical, laboratory and genetic risk factors into a single score that can be used to help estimate time to first treatment as well as overall survival.

    ≤65 years
    0
    >65 years
    +1
    Binet A or Rai 0
    0
    Binet B-C or Rai I-IV
    +1
    ≤3.5
    0
    >3.5
    +2
    Mutated
    0
    Unmutated
    +2
    No abnormalities
    0
    Deletion 17p (FISH) and/or TP53 mutation (sequencing)
    +4

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights

    Advice

    • The CLL-IPI categorizes patients into four risk groups from low risk to very high risk. The decision to treat should not be based on the risk score, since it has not been evaluated for that purpose.
    • Indications for treatment remain the same, but higher risk patients may warrant closer initial monitoring.

    Management

    • Guidelines have not yet incorporated the CLL-IPI scoring system into management algorithms.
    • Risk categories should be used to inform prognosis, and closer monitoring for higher risk patients should be considered.
    • Notably, survival estimates were based on assessments from before the era of targeted therapies for CLL, and this should be taken into consideration when counseling patients.
    Content Contributors
    About the Creator
    Dr. Michael Hallek
    Are you Dr. Michael Hallek?
    Content Contributors